TRANSMEDICS GROUP INC (TMDX) Stock Fundamental Analysis
USA - NASDAQ:TMDX - US89377M1099 - Common Stock
124.98 USD
+0.52 (+0.42%)
123.7 USD
-1.28 (-1.02%)
Taking everything into account, TMDX scores 6 out of 10 in our fundamental rating. TMDX was compared to 189 industry peers in the Health Care Equipment & Supplies industry. TMDX has an excellent financial health rating, but there are some minor concerns on its profitability. TMDX is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, TMDX could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
TMDX had positive earnings in the past year.
In the past year TMDX had a positive cash flow from operations.
TMDX had negative earnings in 4 of the past 5 years.
TMDX had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
TMDX's Return On Assets of 9.70% is amongst the best of the industry. TMDX outperforms 92.59% of its industry peers.
TMDX has a Return On Equity of 25.83%. This is amongst the best in the industry. TMDX outperforms 96.30% of its industry peers.
The Return On Invested Capital of TMDX (8.75%) is better than 87.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.83% | ||
| ROIC | 8.75% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Profit Margin value of 16.20%, TMDX belongs to the best of the industry, outperforming 92.59% of the companies in the same industry.
TMDX has a Operating Margin of 16.94%. This is amongst the best in the industry. TMDX outperforms 86.77% of its industry peers.
TMDX's Gross Margin of 60.28% is fine compared to the rest of the industry. TMDX outperforms 60.85% of its industry peers.
In the last couple of years the Gross Margin of TMDX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
2. Health
2.1 Basic Checks
TMDX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, TMDX has more shares outstanding
Compared to 5 years ago, TMDX has more shares outstanding
TMDX has a better debt/assets ratio than last year.
2.2 Solvency
An Altman-Z score of 5.35 indicates that TMDX is not in any danger for bankruptcy at the moment.
TMDX's Altman-Z score of 5.35 is fine compared to the rest of the industry. TMDX outperforms 79.37% of its industry peers.
The Debt to FCF ratio of TMDX is 4.24, which is a neutral value as it means it would take TMDX, 4.24 years of fcf income to pay off all of its debts.
TMDX's Debt to FCF ratio of 4.24 is amongst the best of the industry. TMDX outperforms 80.42% of its industry peers.
A Debt/Equity ratio of 1.43 is on the high side and indicates that TMDX has dependencies on debt financing.
TMDX has a Debt to Equity ratio of 1.43. This is in the lower half of the industry: TMDX underperforms 79.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Altman-Z | 5.35 |
ROIC/WACC1.09
WACC8.06%
2.3 Liquidity
TMDX has a Current Ratio of 7.69. This indicates that TMDX is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.69, TMDX belongs to the best of the industry, outperforming 88.36% of the companies in the same industry.
A Quick Ratio of 7.13 indicates that TMDX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 7.13, TMDX belongs to the best of the industry, outperforming 89.95% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 162.77% over the past year.
TMDX shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.20%.
The Revenue has been growing by 79.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
3.2 Future
TMDX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 44.52% yearly.
Based on estimates for the next years, TMDX will show a very strong growth in Revenue. The Revenue will grow by 21.23% on average per year.
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
3.3 Evolution
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 50.60, TMDX can be considered very expensive at the moment.
68.25% of the companies in the same industry are more expensive than TMDX, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 25.67, TMDX is valued quite expensively.
TMDX is valuated quite expensively with a Price/Forward Earnings ratio of 42.83.
TMDX's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. TMDX is cheaper than 70.90% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 31.86, TMDX is valued a bit more expensive.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.6 | ||
| Fwd PE | 42.83 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, TMDX is valued a bit cheaper than 69.84% of the companies in the same industry.
77.78% of the companies in the same industry are more expensive than TMDX, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.31 | ||
| EV/EBITDA | 35.34 |
4.3 Compensation for Growth
TMDX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TMDX's earnings are expected to grow with 53.74% in the coming years.
PEG (NY)0.31
PEG (5Y)N/A
EPS Next 2Y69.97%
EPS Next 3Y53.74%
5. Dividend
5.1 Amount
No dividends for TMDX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
124.98
+0.52 (+0.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners111.43%
Inst Owner Change-0.57%
Ins Owners2.96%
Ins Owner Change2.28%
Market Cap4.26B
Revenue(TTM)566.35M
Net Income(TTM)91.77M
Analysts83.16
Price Target149.33 (19.48%)
Short Float %24.1%
Short Ratio8.85
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)92.22%
Min EPS beat(2)84.39%
Max EPS beat(2)100.04%
EPS beat(4)4
Avg EPS beat(4)92.06%
Min EPS beat(4)16.42%
Max EPS beat(4)167.38%
EPS beat(8)7
Avg EPS beat(8)202.42%
EPS beat(12)10
Avg EPS beat(12)118.6%
EPS beat(16)12
Avg EPS beat(16)90.24%
Revenue beat(2)1
Avg Revenue beat(2)0.71%
Min Revenue beat(2)-2.93%
Max Revenue beat(2)4.34%
Revenue beat(4)3
Avg Revenue beat(4)5.83%
Min Revenue beat(4)-2.93%
Max Revenue beat(4)13.8%
Revenue beat(8)6
Avg Revenue beat(8)7.35%
Revenue beat(12)10
Avg Revenue beat(12)12.14%
Revenue beat(16)14
Avg Revenue beat(16)18.13%
PT rev (1m)-0.07%
PT rev (3m)-2.32%
EPS NQ rev (1m)-0.31%
EPS NQ rev (3m)11.52%
EPS NY rev (1m)-0.22%
EPS NY rev (3m)30.79%
Revenue NQ rev (1m)0.03%
Revenue NQ rev (3m)2.36%
Revenue NY rev (1m)-0.02%
Revenue NY rev (3m)3.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 50.6 | ||
| Fwd PE | 42.83 | ||
| P/S | 7.52 | ||
| P/FCF | 35.31 | ||
| P/OCF | 23.94 | ||
| P/B | 11.99 | ||
| P/tB | 12.47 | ||
| EV/EBITDA | 35.34 |
EPS(TTM)2.47
EY1.98%
EPS(NY)2.92
Fwd EY2.33%
FCF(TTM)3.54
FCFY2.83%
OCF(TTM)5.22
OCFY4.18%
SpS16.61
BVpS10.42
TBVpS10.02
PEG (NY)0.31
PEG (5Y)N/A
Graham Number24.06
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 9.7% | ||
| ROE | 25.83% | ||
| ROCE | 11.08% | ||
| ROIC | 8.75% | ||
| ROICexc | 18.94% | ||
| ROICexgc | 19.61% | ||
| OM | 16.94% | ||
| PM (TTM) | 16.2% | ||
| GM | 60.28% | ||
| FCFM | 21.3% |
ROA(3y)-4.07%
ROA(5y)-12.78%
ROE(3y)-7.35%
ROE(5y)-22.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.32%
GM growth 5Y0.21%
F-Score7
Asset Turnover0.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.43 | ||
| Debt/FCF | 4.24 | ||
| Debt/EBITDA | 4.18 | ||
| Cap/Depr | 225.79% | ||
| Cap/Sales | 10.12% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 146.67% | ||
| Profit Quality | 131.47% | ||
| Current Ratio | 7.69 | ||
| Quick Ratio | 7.13 | ||
| Altman-Z | 5.35 |
F-Score7
WACC8.06%
ROIC/WACC1.09
Cap/Depr(3y)951.97%
Cap/Depr(5y)615.69%
Cap/Sales(3y)34.99%
Cap/Sales(5y)23.68%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)162.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%450%
EPS Next Y162.03%
EPS Next 2Y69.97%
EPS Next 3Y53.74%
EPS Next 5Y44.52%
Revenue 1Y (TTM)41.2%
Revenue growth 3Y144.36%
Revenue growth 5Y79.64%
Sales Q2Q%32.24%
Revenue Next Year39.7%
Revenue Next 2Y29.73%
Revenue Next 3Y25.57%
Revenue Next 5Y21.23%
EBIT growth 1Y205.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year292.7%
EBIT Next 3Y89.1%
EBIT Next 5Y68.49%
FCF growth 1Y187.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y801.58%
OCF growth 3YN/A
OCF growth 5YN/A
TRANSMEDICS GROUP INC / TMDX FAQ
Can you provide the ChartMill fundamental rating for TRANSMEDICS GROUP INC?
ChartMill assigns a fundamental rating of 6 / 10 to TMDX.
What is the valuation status for TMDX stock?
ChartMill assigns a valuation rating of 5 / 10 to TRANSMEDICS GROUP INC (TMDX). This can be considered as Fairly Valued.
How profitable is TRANSMEDICS GROUP INC (TMDX) stock?
TRANSMEDICS GROUP INC (TMDX) has a profitability rating of 5 / 10.
Can you provide the PE and PB ratios for TMDX stock?
The Price/Earnings (PE) ratio for TRANSMEDICS GROUP INC (TMDX) is 50.6 and the Price/Book (PB) ratio is 11.99.
What is the financial health of TRANSMEDICS GROUP INC (TMDX) stock?
The financial health rating of TRANSMEDICS GROUP INC (TMDX) is 7 / 10.